A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

PURPOSE: UCN-01 (7-hydroxystaurosporine) is a multi-targeted protein kinase inhibitor that exhibits synergistic activity with DNA-damaging agents in preclinical studies. We conducted a Phase I study to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetic, and pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Fracasso, Paula M., Williams, Kerry J., Chen, Ronald C., Picus, Joel, Ma, Cynthia X., Ellis, Matthew J., Tan, Benjamin R., Pluard, Timothy J., Adkins, Douglas R., Naughton, Michael J., Rader, Janet S., Arquette, Matthew A., Fleshman, James W., Creekmore, Allison N., Goodner, Sherry A., Wright, Lisa P., Guo, Zhanfang, Ryan, Christine E., Tao, Yu, Soares, Eliane M., Cai, Shi-rong, Lin, Li, Dancey, Janet, Rudek, Michelle A., McLeod, Howard L., Piwnica-Worms, Helen
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102212/
https://www.ncbi.nlm.nih.gov/pubmed/20694727
http://dx.doi.org/10.1007/s00280-010-1410-1

Ejemplares similares

Ejemplares similares